.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Cantor Fitzgerald
Queensland Health
Farmers Insurance
Dow
McKinsey
Citi
Cipla
Fuji
Novartis

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021546

« Back to Dashboard

NDA 021546 describes REBETOL, which is a drug marketed by Merck Sharp Dohme and Schering and is included in two NDAs. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the REBETOL profile page.

The generic ingredient in REBETOL is ribavirin. There are fifteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the ribavirin profile page.

Summary for 021546

Tradename:1
Applicant:1
Ingredient:1
Patents:6
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Pharmacology for NDA: 021546

Ingredient-typeNucleoside Analog

Medical Subject Heading (MeSH) Categories for 021546

Suppliers and Packaging for NDA: 021546

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
REBETOL ribavirin SOLUTION;ORAL 021546 NDA Merck Sharp & Dohme Corp. 0085-1318 0085-1318-01 1 BOTTLE in 1 CARTON (0085-1318-01) > 100 mL in 1 BOTTLE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength40MG/ML
Approval Date:Jul 29, 2003TE:RLD:Yes
Patent:► SubscribePatent Expiration:Mar 21, 2018Product Flag?Substance Flag?Delist Request?Y
Patent:► SubscribePatent Expiration:May 1, 2017Product Flag?Substance Flag?Delist Request?Y
Patent:► SubscribePatent Expiration:May 1, 2017Product Flag?Substance Flag?Delist Request?Y

Expired Orange Book Patents for NDA: 021546

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
ScheringREBETOLribavirinSOLUTION;ORAL021546-001Jul 29, 2003► Subscribe► Subscribe
ScheringREBETOLribavirinSOLUTION;ORAL021546-001Jul 29, 2003► Subscribe► Subscribe
ScheringREBETOLribavirinSOLUTION;ORAL021546-001Jul 29, 2003► Subscribe► Subscribe
ScheringREBETOLribavirinSOLUTION;ORAL021546-001Jul 29, 2003► Subscribe► Subscribe
ScheringREBETOLribavirinSOLUTION;ORAL021546-001Jul 29, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Express Scripts
Queensland Health
Argus Health
Moodys
Medtronic
Fuji
Baxter
QuintilesIMS
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot